Recurrent Head and Neck Squamous Cell Carcinoma Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0057896 (Recurrent Head and Neck Squamous Cell Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04007744Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsTreatment